期刊
HUMAN MOLECULAR GENETICS
卷 28, 期 R1, 页码 R88-R94出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddz139
关键词
-
资金
- National Institutes of Health [HL051670, HL91842, HL123482]
- Cystic Fibrosis Foundation
- University of Iowa Center for Gene Therapy [DK54759]
- Roy J. Carver Chair in Molecular Medicine
- Roy J. Carver Chair in Pulmonary Research
Cystic fibrosis (CF) is a multiorgan recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Gene therapy efforts have focused on treating the lung, since it manifests the most significant life-threatening disease. Over two decades have past since the first CF lung gene therapy trials and significant advances in the therapeutic implementation of pharmacologic CFTR modulators have renewed the field's focus on developing gene therapies for the 10% of CF patients these modulators cannot help. This review summarizes recent progress made in developing vectors for airway transduction and CF animal models required for understanding the relevant cellular targets in the lung and testing the efficacy of gene therapy approaches. We also highlight future opportunities in emerging gene editing strategies that may offer advantages for treating diseases like CF where the gene target is highly regulated at the cellular level. The outcomes of CF lung gene therapy trials will likely inform productive paths toward gene therapy for other complex genetic disorders, while also advancing treatments for all CF patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据